Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models.
about
Profile of Mark E. DavisClinical Translation of Nanomedicine.Disulfide cross-linked phosphorylcholine micelles for triggered release of camptothecin.Controlled synthesis of camptothecin-polylactide conjugates and nanoconjugatesNanodrug delivery systems: a promising technology for detection, diagnosis, and treatment of cancer.Tumor-associated macrophages are predominant carriers of cyclodextrin-based nanoparticles into gliomas.Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release.Folding graft copolymer with pendant drug segments for co-delivery of anticancer drugsSelf-assembled nanoscale coordination polymers with trigger release properties for effective anticancer therapyMR cholangiography demonstrates unsuspected rapid biliary clearance of nanoparticles in rodents: implications for clinical translation.First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignanciesPolymer-drug conjugates: recent development in clinical oncologyCRLX101 (formerly IT-101)-A Novel Nanopharmaceutical of Camptothecin in Clinical DevelopmentConscripts of the infinite armada: systemic cancer therapy using nanomaterials.The formulation of aptamer-coated paclitaxel-polylactide nanoconjugates and their targeting to cancer cellsAnticancer Camptothecin-N-Poly(lactic acid) Nanoconjugates with Facile Hydrolysable Linker.Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models.Nanotechnology for cancer treatment.In vivo tumor targeting of gold nanoparticles: effect of particle type and dosing strategyTargeted nanoparticles for image-guided treatment of triple-negative breast cancer: clinical significance and technological advancesPolymeric Micelle-Mediated Delivery of DNA-Targeting Organometallic Complexes for Resistant Ovarian Cancer Treatment.HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy.Linear cyclodextrin-containing polymers and their use as delivery agents.Serial diffusion MRI to monitor and model treatment response of the targeted nanotherapy CRLX101Targeted polymeric therapeutic nanoparticles: design, development and clinical translationPolymer-drug conjugates as modulators of cellular apoptosis.Nanotechnology in the targeted drug delivery for bone diseases and bone regeneration.Small-molecule delivery by nanoparticles for anticancer therapyAlpha-methylprednisolone conjugated cyclodextrin polymer-based nanoparticles for rheumatoid arthritis therapyCancer therapies utilizing the camptothecins: a review of the in vivo literatureFactors affecting the clearance and biodistribution of polymeric nanoparticles.Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle.NANOSCALE SELF-ASSEMBLY FOR DELIVERY OF THERAPEUTICS AND IMAGING AGENTS.Advances of cancer therapy by nanotechnology.Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements.Synthesis and in vivo antitumor efficacy of PEGylated poly(l-lysine) dendrimer-camptothecin conjugates.Cyclodextrin-based supramolecular systems for drug delivery: recent progress and future perspectivePreclinical effects of CRLX101, an investigational camptothecin-containing nanoparticle drug conjugate, on treating glioblastoma multiforme via apoptosis and antiangiogenesis.Priming nanoparticle-guided diagnostics and therapeutics towards human organs-on-chips microphysiological systemNanoparticles containing insoluble drug for cancer therapy.
P2860
Q24646416-CB795B44-9173-4609-827B-C429D1FF859AQ30355939-BCBF4F96-2F54-4067-AB12-5CBDC7DBA5C6Q30641959-9AB17091-2EAD-4171-964E-10F7B716FC33Q33601744-20D5CD8F-4130-437D-946F-B4AAA42E4284Q33681168-14D35031-AF82-426F-89D9-ECCDE567B646Q33837621-B0F11691-EFFF-4E33-9092-86554B01560DQ33902253-13E68BD8-CFD7-4A55-870E-FEE672E997BAQ33936160-2F000F41-AB17-4D57-95F0-46A95DA08F05Q34275000-778CB597-0683-4C85-95C8-E8EA5C8A8E31Q34315778-14A9E57D-F639-44C0-AAC4-FA911C23A5D8Q34327123-3CD601A6-34DF-41A1-976F-2E63A541817BQ34656003-780443FC-32BE-4E47-BBE3-3417303740EBQ35237593-08F90FE2-B8EF-4458-8662-5F86B782ACC2Q35545342-4387E55B-0905-4507-8F9A-DA2FCE319AD8Q35567561-98F412E4-2D75-48A6-BF86-BEC18D165F84Q35628729-A68005B9-36AA-465E-82E3-A63465E9C48FQ35631349-F4B7E4B7-47E8-4E63-8F72-A8FC2B4D7D1EQ35737878-7E92343C-9FED-4D4A-85E1-4EA523572A75Q35822275-E5C42845-E6FB-4C00-91CD-DCA82DFE032FQ36157045-6A90921C-926A-41B5-A8D6-9831A5E7E309Q36253687-031D5A19-2C9F-4846-A26C-7FBC03B565E3Q36448817-4BA83A9A-2EAB-4D09-BCB9-D300966BE344Q36583740-2EFB2D4B-B01D-400B-97FF-FE7DB769CF96Q36815253-01C15B86-4CF6-4109-A05D-8A7CD528CA43Q36934007-0146399A-8F0F-4DB6-9164-04DAEA0F46EBQ36956674-3C479098-85CD-4586-8916-4870B5445D55Q36975264-90B7B2AB-E2D5-404F-A09E-6AEF331A5246Q37059874-6B6DB81C-3F2D-48D8-AED6-C57F7B496D7FQ37062611-4D520077-64BF-4F10-81CF-54C094416090Q37069556-E783A2A5-90E0-4577-86CC-B0289B6659BEQ37146591-A6B9B064-D4B7-4683-AE90-7E81BD40D739Q37173162-B30CD276-C859-427D-BBF4-91A8E617D3B3Q37201160-6293856E-3BF7-4F8B-8D90-9740B2529043Q37234202-A8673C91-5CC8-4B32-A511-9B1E1BA0AFE0Q37245063-035EC29C-3A05-475F-8A37-61D29EB345E0Q37394856-CB9A91EA-A87B-4A07-B33B-4B65334F2A66Q37454370-E5FC94C0-C711-47B7-874A-8A33FE793BE9Q37520563-51CB6A74-B752-4E24-B757-863CC19DAE82Q37610379-832BC8E3-8E61-4975-B90B-DD04CBB5D17DQ37693046-CBC37B77-FF69-41F3-9637-163BF06C844E
P2860
Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մարտին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Preclinical efficacy of the ca ...... 101 in multiple cancer models.
@ast
Preclinical efficacy of the ca ...... 101 in multiple cancer models.
@en
Preclinical efficacy of the ca ...... 101 in multiple cancer models.
@nl
type
label
Preclinical efficacy of the ca ...... 101 in multiple cancer models.
@ast
Preclinical efficacy of the ca ...... 101 in multiple cancer models.
@en
Preclinical efficacy of the ca ...... 101 in multiple cancer models.
@nl
prefLabel
Preclinical efficacy of the ca ...... 101 in multiple cancer models.
@ast
Preclinical efficacy of the ca ...... 101 in multiple cancer models.
@en
Preclinical efficacy of the ca ...... 101 in multiple cancer models.
@nl
P2093
P1476
Preclinical efficacy of the ca ...... 101 in multiple cancer models.
@en
P2093
Beth Hollister
Derek W Bartlett
Jeremy D Heidel
Jianjun Cheng
Jungyeong Hwang
Mark E Davis
Thomas Schluep
P304
P356
10.1158/1078-0432.CCR-05-1566
P407
P577
2006-03-01T00:00:00Z